Table 2. Logistic regression analysis for predictors of MTB culture-positive TB in sputum smear-negative HIV-infected presumptive TB**.
Characteristics | crude OR (95%CI) | P-value | Adjusted OR (95%CI) | P-value |
---|---|---|---|---|
Female gender | 0.59(0.37–0.94) | 0.025 | - | - |
Age per 5 year increase | 0.91 (0.79–1.05) | 0.194 | - | - |
Hospitalization | 2.13 (1.23–3.70) | 0.007 | - | - |
CD4(cells/μl); per 50 cells increase | 0.87 (0.80–0.93) | 0.000 | 0.93 (0.86–1.01) | 0.070 |
Previous TB treatment | 0.34 (0.16–0.73) | 0.006 | 0.41 (0.17–0.99) | 0.049 |
Not on ART treatment | 1.62 (0.99–2.66) | 0.054 | 1.39 (0.76–2.53) | 0.284 |
Cotrimoxazole prophylaxis | .73 (0.31–1.71 | 0.467 | - | - |
Cough duration (weeks) | 1.02 (0.99–1.06) | 0.207 | - | - |
Weight (per kg increase) | 1.00 (0.98–1.02) | 0.944 | - | - |
Abnormal CXR | 4.01 (2.08–7.73 | 0.000 | 3.68 (1.76–7.71) | 0.001 |
Positive urine TB-LAM | 8.15 (4.48–14.84 | 0.000 | 6.21 (3.14–12.27) | 0.000 |
** N = 381 with complete records.
The model adjusted for CD4 cell count, previous TB treatment, antiretroviral therapy, CXR findings, ART therapy and urine TB-LAM test
Abbreviations: TB, tuberculosis; ART, antiretroviral therapy; CXR, chest X-ray; LAM, lipoarabinomannan; IQR, inter-quartile range; OR, odds ratio; CI, confidence intervals.